Spike-expressing vectors for lentiviral pseudotyping
pLV-SARS2-S-d19 | Unit size | Cat. code | Docs | Qty | Price |
---|---|---|---|---|---|
SARS-CoV-2 Spike gene (original D614) for lentiviral pseudotyping |
20 µg |
plv-cov2-sd19 |
pLV-SARS2-S-d19 (D614G) | Unit size | Cat. code | Docs | Qty | Price |
---|---|---|---|---|---|
SARS-CoV-2 Spike gene (G614-variant) for lentiviral pseudotyping |
20 µg |
plv-cov2-sd19g |
You may also need : Human ACE2 expressing HEK293 cells | View more associated products ▼
SARS-CoV-2 spike plasmid for pseudotyping lentiviral particles
InvivoGen also offers:
• SARS-CoV-2-Cellular Receptor Genes
• ACE2-expressing Cell Line
pLV-SARS2-S-d19 and pLV-SARS2-S-d19 (D614G) plasmids have been designed for pseudotyping lentiviral particles with the SARS-CoV-2 Spike (S) protein. Pseudotyped particle production involves the co-transfection of 293T cells with a reporter protein vector (e.g. GFP), one or several plasmids encoding the necessary lentiviral proteins, and the pseudotyping pLV-SARS2-S-d19 plasmids. The transfected cells produce SARS‑CoV‑2 Spike (S)‑pseudotyped lentiviral particles, which can then be used to infect permissive cells, such as ACE2‑expressing HEK293-derived cells and ACE2‑TMPRSS2‑expressing A549-derived cells.
Interestingly, lentiviral particles expressing the globally dominant Spike G614‑variant have been shown to have greater infectivity of ACE2-expressing target cells, when compared to particles expressing the original D614 Spike protein [1,2]. Furthermore, there is evidence that Spike (D614 or G614)-pseudotyped particles trigger syncytia (i.e. cell fusion) in cells expressing hACE2 and TMPRSS2 [3, see figures].
Plasmid Description
pLV-SARS2-S-d19 and pLV-SARS2-S-d19 (D614G) plasmids encode the Spike (S) gene (codon‑optimized) from the original SARS-CoV-2 Wuhan‑Hu-1 (D614) isolate or the globally‑dominant G614-variant (D614G mutation), respectively [4]. Furthermore, to improve the expression of the S protein in pseudovirions and cell lines, the last 19 amino acids (d19), which contain the ER‑retention motif, have been removed [2, 5].
These plasmids feature a potent mammalian expression cassette composed of the ubiquitous human-(h)CMV composite promoter, a rabbit β-globin intron directly upstream of the spike gene, and a rabbit β-globin polyadenylation (pAn) signal. The spike coding sequence includes the SARS-CoV-2 signal sequence and the S1/S2 furin cleavage site. These plasmids are selectable with ampicillin in E. coli.
Quality Control
- Fully sequenced ORF
- Predominant supercoiled conformation
- Generation of infectious SARS-CoV-2 Spike (D614 or G614)-pseudotyped lentiviral particles using pLV-SARS2-S-d19 and pLV-SARS2-S-d19 (D614G), respectively, has been validated (see figures).
Gene Description
Spike (S) is a structural glycoprotein expressed on the surface of SARS‑CoV-2. It mediates membrane fusion and viral entry into target cells upon binding to the host receptor ACE2 and its cleavage by cellular proteases such as TMPRSS2 [6]. The S protein consists of an N-terminal ectodomain, a transmembrane anchor, and a short C‑terminal cytoplasmic tail. The ectodomain contains the S1 subunit, which encodes the receptor-binding domain (RBD), as well as the S2 subunit, needed for membrane fusion [7]. Notably, the C‑terminal cytoplasmic tail of the S protein encodes a presumptive endoplasmic reticulum (ER)‑retention motif (KxHxx), which has previously been shown to enable the accumulation of SARS‑CoV S proteins at the ER‑Golgi intermediate compartment (ERGIC) and facilitate their incorporation into new virions [8]. The removal of this motif (d19) has been shown to increase the expression of the spike protein in pseudovirions [2,5].
Learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.
References
1. Daniloski, Z. et al. 2020. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. bioRxiv. doi:10.1101/2020.06.14.151357
2. Johnson, M.C. et al. 2020. Optimized pseudotyping conditions for the SARS-COV2 Spike glycoprotein. J Virol. 94(21):e01062-20
3. Buchrieser, J. et al. 2020. Syncytia formation by SARS-CoV-2 infected cells. EMBO J, e106267.
4. Korber B. et al. 2020. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases the infectivity of the COVID-19 virus. Cell. 182:1-16.
5. Ou, X. et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620.
6. Hoffmann M. et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:1-16.
7. Walls A.C., et al. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281-292.e6.
8. Ujike, M. et al. 2016. The contribution of the cytoplasmic retrieval signal of severe acute respiratory syndrome coronavirus to intracellular accumulation of S proteins and incorporation of S protein into virus-like particles. J Gen Virol 97, 1853-1864.
Specifications
pLV-SARS2-S-d19 (D614):
- Origin: Wuhan-Hu-1 isolate
- ORF size: Codon optimized 3765 bp
-
Sequencing primers:
- Forward rbt β-globin intron: TGGTTACAATGATATACACTG
- Reverse rbt β-globin pAn: CTCAAGGGGCTTCATGATGTC
pLV-SARS2-S-d19 (D614G):
- Origin: pUNO1-SARS2-S with D614G mutation (original sequence)
- ORF size: Codon optimized 3765 bp
-
Sequencing primers:
- Forward rbt β-globin intron: TGGTTACAATGATATACACTG
- Reverse rbt β-globin pAn: CTCAAGGGGCTTCATGATGTC
Contents
pLV-SARS2-S-d19 (D614 or D614G) are provided as follows:
- 20 μg of lyophilized DNA
The product is shipped at room temperature.
Lyophilized DNA should be stored at -20 °C.
Resuspended DNA should be stored at -20 °C and is stable up to 1 year.
Back to the top